147 related articles for article (PubMed ID: 31417315)
1. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
[TBL] [Abstract][Full Text] [Related]
2. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.
Ando T; Hosokawa A; Yoshita H; Ueda A; Kajiura S; Mihara H; Nanjo S; Fujinami H; Nishikawa J; Ogawa K; Nakajima T; Imura J; Sugiyama T
Gastroenterol Res Pract; 2015; 2015():425876. PubMed ID: 26199623
[TBL] [Abstract][Full Text] [Related]
3. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
[TBL] [Abstract][Full Text] [Related]
4. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
[TBL] [Abstract][Full Text] [Related]
5. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
Funasaka C; Kanemasa Y; Kageyama A; Shimoyama T; Omuro Y
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1205-1208. PubMed ID: 32829355
[TBL] [Abstract][Full Text] [Related]
7. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
[TBL] [Abstract][Full Text] [Related]
8. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C
J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273
[TBL] [Abstract][Full Text] [Related]
9. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
11. Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
Igawa S; Ono T; Kasajima M; Manabe H; Fukui T; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Sasaki J; Naoki K
Cancer Manag Res; 2020; 12():4911-4921. PubMed ID: 32606979
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients.
Kushiro K; Watanabe S; Goto Y; Fujisaki T; Yanagimura N; Ohtsubo A; Shoji S; Nozaki K; Tanaka T; Saida Y; Sato Y; Ota T; Koshio J; Hayashi Y; Miyabayashi T; Matsumoto N; Ichikawa K; Koyama K; Kikuchi T
Transl Lung Cancer Res; 2022 Sep; 11(9):1858-1865. PubMed ID: 36248339
[TBL] [Abstract][Full Text] [Related]
14. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Igawa S; Shirasawa M; Ozawa T; Nishinarita N; Okuma Y; Ono T; Sugimoto A; Kurahayashi S; Sugita K; Sone H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Aug; 9(8):967-973. PubMed ID: 29870153
[TBL] [Abstract][Full Text] [Related]
15. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride.
Kim YH; Mio T; Masago K; Irisa K; Sakamori Y; Mishima M
Oncol Lett; 2010 May; 1(3):569-572. PubMed ID: 22966345
[TBL] [Abstract][Full Text] [Related]
17. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
18. Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.
Kasahara N; Wakuda K; Omori S; Nakashima K; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Mori K; Watanabe R; Endo M; Nakajima T; Yamada M; Takahashi T
Mol Clin Oncol; 2017 May; 6(5):718-722. PubMed ID: 28529747
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Watanabe H; Karayama M; Yasui H; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
Cancer Treat Res Commun; 2021; 29():100493. PubMed ID: 34844181
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
